{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:14:47Z","timestamp":1776708887582,"version":"3.51.2"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shionogi Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cefiderocol is a new siderophore cephalosporin for treating severe bacterial infections by Gram-negative pathogens in adults. Significant elimination of the drug will probably occur as a result of kidney replacement therapy, but there are currently insufficient pharmacokinetic data to guide dosing during prolonged intermittent kidney replacement therapy (PIKRT) or the use of the pathogen adsorber Seraph 100.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods\/case reports<\/jats:title>\n                    <jats:p>Pharmacokinetic data were obtained from two critically ill patients undergoing PIKRT and hemoperfusion with the pathogen adsorber Seraph 100. Cefiderocol levels in plasma and dialysate samples were quantified using liquid chromatography with tandem mass spectrometry to evaluate the impact of extracorporeal therapy modalities on cefiderocol pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median cefiderocol dialyser clearance was 80.94 (38.7\u201387) mL\/min, while the Seraph 100 showed no significant clearance [\u22121.8 (\u22127.9 to 3.6) mL\/min]. The cefiderocol concentration in the total spent dialysate suggests a total elimination of 1350 and 400\u2005mg of cefiderocol, or 68% and 40% of the administered dose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Cefiderocol is substantially eliminated by PIKRT, but not during hemoperfusion with the Seraph 100. Consequently, dosage adjustments may be necessary depending on the intensity of the PIKRT procedure. Doses used for patients with normal renal function may be required to prevent underdosing during intensive PIKRT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf496","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:25:29Z","timestamp":1767011129000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0815-7788","authenticated-orcid":false,"given":"Julius J","family":"Schmidt","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hagemann","sequence":"additional","affiliation":[{"name":"Medical Clinic V | Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig , Braunschweig ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Hillebrand","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Scherneck","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universit\u00e4t Braunschweig , Braunschweig ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fritz","family":"S\u00f6rgel","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research , N\u00fcrnberg-Heroldsberg ,","place":["Germany"]},{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University of Duisburg-Essen , Essen ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Kinzig","sequence":"additional","affiliation":[{"name":"Institute for Biomedical and Pharmaceutical Research , N\u00fcrnberg-Heroldsberg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8110-9064","authenticated-orcid":false,"given":"Jan T","family":"Kielstein","sequence":"additional","affiliation":[{"name":"Medical Clinic V | Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig , Braunschweig ,","place":["Germany"]},{"name":"Institute of Pharmacology, Toxicology and Clinical Pharmacy, Technische Universit\u00e4t Braunschweig , Braunschweig ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"2026013006350529800_dkaf496-B1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/antibiotics13010046","article-title":"Multidrug-resistant sepsis: a critical healthcare challenge","volume":"13","author":"Kumar","year":"2024","journal-title":"Antibiotics"},{"key":"2026013006350529800_dkaf496-B2","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/cid\/ciab757","article-title":"Cefiderocol: a new cephalosporin stratagem against multidrug-resistant Gram-negative bacteria","volume":"74","author":"Ong\u2019uti","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026013006350529800_dkaf496-B3","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s10096-025-05108-6","article-title":"Effectiveness and safety of cefiderocol treatment in patients with Gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","volume":"44","author":"Torre-Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026013006350529800_dkaf496-B4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","article-title":"Cefiderocol, a siderophore cephalosporin for Gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment","volume":"57","author":"Katsube","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2026013006350529800_dkaf496-B5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s40262-021-01086-y","article-title":"Pharmacokinetics, pharmacodynamics, and dose optimization of cefiderocol during continuous renal replacement therapy","volume":"61","author":"Wenzler","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"2026013006350529800_dkaf496-B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00063-024-01153-9","article-title":"[Extracorporeal removal of pathogens using a biomimetic adsorber-A new treatment strategy for the intensive care unit: Seraph\u00ae 100 Microbind\u00ae affinity blood filter and its fields of application]","volume":"120","author":"Seffer","year":"2025","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"2026013006350529800_dkaf496-B7","author":"Clinical and Laboratory Standards Institute"},{"key":"2026013006350529800_dkaf496-B8","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.3390\/microorganisms11102575","article-title":"Antimicrobial multidrug resistance: clinical implications for infection management in critically ill patients","volume":"11","author":"Kal\u0131n","year":"2023","journal-title":"Microorganisms"},{"key":"2026013006350529800_dkaf496-B9","doi-asserted-by":"publisher","first-page":"e01437-20","DOI":"10.1128\/AAC.01437-20","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic analyses of cefiderocol, a parenteral siderophore cephalosporin, in patients with pneumonia, bloodstream infection\/sepsis, or complicated urinary tract infection","volume":"65","author":"Kawaguchi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013006350529800_dkaf496-B10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jgar.2021.10.014","article-title":"A descriptive case series of pharmacokinetic\/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and\/or ventilator-associated pneumonia treated with cefiderocol","volume":"27","author":"Gatti","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026013006350529800_dkaf496-B11","doi-asserted-by":"publisher","first-page":"ofae451","DOI":"10.1093\/ofid\/ofae451","article-title":"Validation of cefiderocol package insert dosing recommendation for patients receiving continuous renal replacement therapy: a prospective multicenter pharmacokinetic study","volume":"11","author":"Fouad","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026013006350529800_dkaf496-B12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/ckj\/sfaa063","article-title":"In vitro elimination of anti-infective drugs by the Seraph\u00ae 100 Microbind\u00ae affinity blood filter","volume":"13","author":"Schmidt","year":"2020","journal-title":"Clin Kidney J"},{"key":"2026013006350529800_dkaf496-B13","doi-asserted-by":"publisher","first-page":"e02163-17","DOI":"10.1128\/AAC.02163-17","article-title":"Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects","volume":"62","author":"Saisho","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026013006350529800_dkaf496-B14","doi-asserted-by":"publisher","first-page":"100970","DOI":"10.1016\/j.accpm.2021.100970","article-title":"A personalised approach to antibiotic pharmacokinetics and pharmacodynamics in critically ill patients","volume":"40","author":"Heffernan","year":"2021","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2026013006350529800_dkaf496-B15","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"49","author":"Evans","year":"2021","journal-title":"Crit Care Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf496\/66639910\/dkaf496.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/2\/dkaf496\/66639910\/dkaf496.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T11:35:13Z","timestamp":1769772913000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkaf496\/8445315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,19]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf496","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,19]]},"article-number":"dkaf496"}}